Cyllene wins US FDA RMAT designation for EG110A

French genetic medicines company Cyllene Therapeutics announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, EG110A, a first-in-class treatment being developed to address neurogenic detrusor overactivity (NDO) with urinary incontinence.

EG110A is a non-replicating HSV-1 vector designed to selectively silence CGRP+ (type C) sensory neurons responsible for bladder muscle overactivity, whilst preserving normal bladder function. The first of a pipeline of products developed from Cyllene Tx’s proprietary HERMES platform, EG110A’s properties reflect the inherent safety and redosability characteristics possessed by non-replicative herpes vectors.